Are All Patients With IBD at Increased Risk for Colorectal Cancer?

Although inflammatory bowel disease (IBD) increases risk for colorectal cancer (CRC), the risk is only substantial among patients with long-term, extensive colitis. Furthermore, CRC risk is reduced by thiopurine therapy, according to the July issue of Gastroenterology. Laurent Beaugerie et al. collected data from 19,486 patients with IBD (60% with

Read more

How Does PSC Lead to IBD?

Many patients with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD), which becomes more severe after liver transplantation, researchers report in the May issue of Clinical Gastroenterology and Hepatology. These patients might require special immunosuppressive regimens. PSC is a chronic, cholestatic liver disease that eventually leads to cirrhosis

Read more

What are the Effects of IBD Therapy During Pregnancy?

In pregnant women treated for inflammatory bowel diseases (IBD),  infliximab and adalimumab, but not certolizumab, cross the placenta and are detected in infants up to 6 months after birth, according to the March issue of Clinical Gastroenterology and Hepatology (CGH). However, they do not appear to cause birth defects, and women

Read more

Does Depression Increase the Risk for Inflammatory Bowel Disease?

Depression increases the risk for Crohn’s disease in women, according to a study published in the January issue of Clinical Gastroenterology and Hepatology. Psychological factors might therefore contribute to development of this disorder. Anxiety, depression, and other psychological disorders are common in people with Crohn’s disease (CD) and ulcerative colitis

Read more

Who Will Develop Pouchitis After Ileal Pouch–Anal Anastomosis?

Serum markers can be used to identify patients with ulcerative colitis most likely to have inflammatory complications after ileal pouch–anal anastomosis (IPAA), according to the May issue of Clinical Gastroenterology and Hepatology. More than 20% of individuals with ulcerative colitis eventually need surgery for this disease. Patients with fulminant or

Read more

Is Medicine or Surgery the Best Treatment for Crohn’s Disease?

For patients with Crohn’s disease and intra-abdominal abscesses, nonsurgical and surgical management strategies result in similar rates of abscess recurrence and complications, according to the April issue of Clinical Gastroenterology and Hepatology. Crohn’s disease can progress from inflammation and ulceration to bowel damage that includes formation of abscesses, phlegmon, and

Read more

Can Patients With Crohn’s Disease Ever Stop Taking Infliximab?

Half of patients with Crohn’s disease treated with infliximab experience a relapse within the first year after they stop taking the drug, according to a study published in the January issue of Gastroenterology. Drugs such as infliximab inhibit the inflammatory cytokine tumor necrosis factor (TNF) and are effective in reducing

Read more

What Does the Appendix Do, Anyway?

The appendix protects against recurrent infection by Clostridium difficile (C difficile) and possibly other pathogenic bacteria, according to a study published in the December issue of Clinical Gastroenterology and Hepatology. Although the human appendix is considered to be expendable, it contains gut-associated lymphoid tissue (GALT), which processes antigen and regulates

Read more

High Rate of Complications from Colectomy for Ulcerative Colitis

Twenty-seven percent of patients who are treated for ulcerative colitis by colectomy experience postoperative complications, according to a study in the November issue of Clinical Gastroenterology and Hepatology. Most patients with ulcerative colitis are successfully treated with medication, yet some have severe colitis attacks that can be life threatening. Approximately

Read more

Certolizumab and Remission in Some Patients With Crohn’s Disease

The drug certolizumab pegol induces remission in patients with Crohn’s disease who have high baseline levels of inflammation, according to William Sandborn et al. in the August issue of Clinical Gastroenterology and Hepatology. Patients with moderate to severe Crohn’s disease that do not respond conventional therapy are often treated with

Read more